Merck's Vasotec in NHLBI studies
Two randomized, controlled trials are being sponsored by the National Heart, Lung & Blood Institute to determine the effectiveness of enalapril in improving survival of patients with left ventricular dysfunction. Effects of the ACE inhibitor on quality of life, biventricular functions, arrhythmias, exercise tolerance, neurohormonal changes and major morbidity will also be assessed. Studies, which are being conducted at 23 centers in the U.S., Canada and Belgium, will enroll 4,500 asymptomatic congestive heart failure patients to the prevention trial and 2,600 symptomatic patients to the treatment trial.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.